Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Article excerpt
Highlighted: the sentence this signal was extracted from
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI ), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights "This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. "Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey. Caris Assure ® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end. It all comes back to making precision medicine a reality for every patient through a comprehensive, data-driven approach." Recent Operating Highlights Third Quarter 2026 Financial Results Total revenue was $275.4 million for the three...
Keep reading with a free account
The rest of this article, and every signal for Caris Life Sciences, is in your free account.
